Carlyle Expands Device Venture Finance Group

When most industry people hear of The Carlyle Group, they think of it exclusively as a buyout group, and indeed leveraged buyouts are an important part of the global private equity firm's business. But many are surprised to learn that Carlyle has a venture and growth capital operation that maintains a strong commitment to investing in the medical device sector.

When most industry people hear of The Carlyle Group, they think of it exclusively as a buyout group, and indeed leveraged buyouts are an important part of the global private equity firm’s business. But many are surprised to learn that Carlyle has a venture and growth capital operation that maintains a strong commitment to investing in the medical device sector. In fact, Carlyle recently announced that it is expanding its health care venture operations to the West Coast—they had previously been based in New York and Washington, DC—with the opening of a San Francisco office to be closer to the hub of early-stage medical technology activities in the Bay area. Carlyle is currently investing in devices out of its new $605 million venture and growth fund.

"Medical device investing is the core of what we do in health care venture capital at Carlyle," says Ryan M....

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.